$10.69
+0.11 (+1.04%)
Open$10.57
Previous Close$10.58
Day High$10.70
Day Low$10.56
52W High$39.75
52W Low$6.27
Volume—
Avg Volume39.8K
Market Cap22.77M
P/E Ratio—
EPS$-22.60
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+115.2% upside
Current
$10.69
$10.69
Target
$23.00
$23.00
$15.62
$23.00 avg
$28.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.59M | 3.48M | 3.01M |
| Net Income | 732.2K | 573.7K | 520.4K |
| Profit Margin | 20.4% | 16.5% | 17.3% |
| EBITDA | 1.09M | 1.00M | 849.7K |
| Free Cash Flow | 537.7K | 589.4K | 453.2K |
| Rev Growth | +3.4% | -1.6% | +9.6% |
| Debt/Equity | 0.28 | 0.26 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |